Management Team – Cumberland Pharmaceuticals

Fostering Culture,
Inspiring Performance,
Encouraging Teamwork

Management Team

A.J. Kazimi

Chief Executive Officer

A.J. Kazimi is the Chairman of the Board of Directors and Chief Executive Officer of Cumberland Pharmaceuticals Inc., which he founded in 1999. His career includes over 30 years in the biopharmaceutical industry. At Cumberland, he has overseen the development and FDA approval of key Company brands, while also leading the acquisition of the Company’s other commercial products. He was responsible for Cumberland’s initial public offering and listing on the Nasdaq stock exchange.

Kazimi also serves as Chairman and Chief Executive Officer of Cumberland Emerging Technologies – a joint initiative with Vanderbilt University and the state of Tennessee – designed to support the development of early-stage life sciences programs and companies.

Prior to joining Cumberland, he spent 11 years helping to build Therapeutic Antibodies Inc., an international biopharmaceutical company. As President and Chief Operating Officer, he made key contributions to that company’s growth from its startup phase through its initial public offering and listing on the London stock exchange. Kazimi started his career at Brown-Forman Corporation, rising through a series of management positions.

He is Chairman of the Board for the Gettysburg Foundation, which partners with the National Park Service to preserve their historic military park. He is also a member of the Board of the Tennessee Historical Society and the Owen Advisory Council at the Vanderbilt University Business School.

He previously served on the Board of Directors for the Nashville Health Care Council, an association of the largest concentration of health care companies in the U.S., and the Board of Aegis Sciences Corporation, a federally certified forensic toxicology laboratory, which has twice been sold to private equity investors. Kazimi holds an MBA from the Vanderbilt University Owen Graduate School of Management and a B.S. from the University of Notre Dame.

Kazimi brings strategic insight, leadership, and a history of successful execution to the Company along with a wealth of experience in both the biopharmaceutical industry and the development of emerging companies.

James Herman

Executive Vice President
National Accounts and
Chief Compliance Officer

As Executive Vice President of National Accounts, James Herman handles all national accounts sales, including wholesalers and retail chain buying offices, managed care home offices and federal government accounts. He is also charged with overseeing Cumberland’s corporate compliance efforts.

He has been with Cumberland since 2003 and has over 30 years of pharmaceutical industry experience. From 1998 to 2003, he was with Solvay Pharmaceuticals and served as Director of Managed Care and Director of Trade Affairs and Customer Service. From 1990 to 1998, Herman was with Schwarz Pharma, where he held national sales leadership positions in National Accounts and Managed Care. He holds an MBA from Cardinal Stritch University and a B.S. from Indiana University.

John Hamm

Executive Vice President
National Accounts and
Chief Compliance Officer

John Hamm has over 25 years of finance and accounting experience, with a majority of those years in the health care industry. In his role as Executive Vice President and Chief Financial Officer, he manages all of Cumberland’s finance and accounting activities while continuing to oversee corporate development and legal matters.

Before joining Cumberland in 2019, Hamm was CFO, Partner Consultant with Tatum LLC, a finance and accounting consulting firm. He previously held the positions of Chief Operating Officer and Chief Financial Officer, Pharmacy at HealthSpring, Inc., a managed care organization currently operating as Cigna-HealthSpring.

Prior to that, he was Vice President of Finance at Emdeon Business Services. Emdeon Inc., a health care technology firm that now operates as Change Healthcare Inc., a Nasdaq-listed company with over $3 billion in annual revenue. Hamm holds an MBA in accounting from West Virginia University and a B.S. in business administration with a minor in accounting from Wheeling University. He is a certified management accountant and certified financial manager.

Todd Anthony

Vice President
Organizational Development

Todd Anthony is Vice President of Organizational Development for Cumberland Pharmaceuticals. In this role he oversees human resources, sales training and office administration activities. Anthony joined our company in 2010. During his tenure, he has made many contributions to training and development initiatives as well as human resources activities, including the preparation and implementation of sales training materials for each branded product.

Under his leadership, the Cumberland Academy was established with a core curriculum and advanced courses designed to provide industry expertise and continued learning opportunities for the office employees. Anthony has over 30 years of pharmaceutical training, organizational development and human resource management experience. Prior to joining Cumberland, he held various positions of increasing responsibility at Bayer HealthCare Pharmaceuticals, including sales training, sales management and leadership development. He holds a B.S. in nursing from D’Youville College in Buffalo, New York.

Cheow Choon

Senior Director
International Business

Tan Cheow Choon is the Senior Director of International Business Development for Cumberland Pharmaceuticals. His responsibilities include identifying new partnership opportunities and managing those relationships in the Asian market.

Prior to joining Cumberland, Choon was Vice President of Southeast Asia & Korea at Hospira Inc. His career also includes roles in banking and finance with the United Overseas Bank, Singapore as well as the establishment, development and management of pharmaceutical partnerships across Asia as General Manager, Asia for Mayne & Faulding Pharmaceutical of Australia. Choon holds an M.B.A. from Monash University in Australia and is an accountant earning his bachelor’s degree in accountancy from the National University of Singapore.

Chris Bitterman

Vice President
Sales and Marketing

Chris Bitterman joined Cumberland in 2018 with a distinguished career in acute care and pharmaceutical sales management spanning over 25 years. Highlights include his roles as National Sales Director for Lupin Pharmaceuticals, Daiichi Sankyo and Regional Sales Director for Sanofi Aventis.

At Cumberland, Bitterman first served as the Hospital Sales Director, leading the hospital sales division. In 2022, his role expanded to include the oncology business, and he was promoted to Senior Director of Hospital and Oncology Sales.

Currently, Bitterman serves as the Vice President of Sales and Marketing, where he is responsible for leading the sales and marketing efforts for Cumberland’s commercial portfolio and delivering annual financial objectives. A native of Detroit, Bitterman holds both an MBA and a B.S. from Central Michigan University.

Ines Macias-Perez, Ph.D.

Director
Product Development

Ines Macias-Perez, Ph.D., is a clinical research professional with extensive experience in drug development and program management. In her role as the Director of Product Development at Cumberland Pharmaceuticals, she oversees the strategic planning, execution, and management of clinical and nonclinical programs for the Company’s product portfolio.

Prior to her role at Cumberland, Dr. Macias-Perez held leadership positions at the Radiosurgical Research Institute, where she served as the Executive Director, and Berg Pharma, where she was the Clinical Research Director. She also held positions at renowned institutions Sarah Cannon Research Institute and Vanderbilt University, where she conducted cancer research.

Her expertise spans strategic product innovation, tactical regulatory approaches and identifying unmet medical needs. Macias-Perez has made significant contributions to the field of oncology and rare disease research, with numerous publications and presentations at national conferences. She has also received grants from the FDA Orphan Product Division for clinical trials as well as several honors and awards from Cumberland Pharmaceuticals, including the President’s Award. She holds a Ph.D. from Vanderbilt University in Cancer Biology and an M.S. and B.A. from the University of South Florida.

Adam Mostafa

Managing Director
Banking and Investor Relations

In his role as consulting Managing Director of Banking and Investor Relations, Adam Mostafa is responsible for managing our investment banking activities and supporting our institutional investor interactions. He is an experienced biopharmaceutical investment banker who has worked in corporate finance since 2001.

Prior to joining Cumberland in 2017, Mostafa worked on Wall Street at Cantor Fitzgerald & Co. as Managing Director, Healthcare Investment Banking. There, he was involved predominantly in financing life sciences companies in the specialty pharmaceutical and biotechnology sectors. He also served as a Senior Health Care Investment Banker at both Needham & Company and CRT Capital, where, at the latter, he was also involved in life sciences private equity investments.

Earlier in his career, Mostafa was a portfolio management associate at AQR Capital and a Health Care Investment Banking Analyst at Salomon Smith Barney. Mostafa graduated from Brown University with a B.A. in economics

Fostering Culture, Inspiring Performance, Encouraging Teamwork